Open bypass and endoluminal therapy: Complementary techniques for revascularization in diabetic patients with critical limb ischaemia

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The use of endovascular therapy (EVT) for lower extremity atherosclerosis is markedly increasing while open surgical bypass is in decline. The results of EVT for critical limb ischaemia (CLI) are difficult to evaluate, especially for patients with diabetes. To date, only one randomized, prospective trial has been published comparing EVT with open bypass for CLI. Although early costs and outcomes were equivalent or superior for EVT, after 2 years, surgery was associated with a significantly reduced risk of future amputation and death. Approximately, 40-50% of diabetic patients with CLI can be initially treated with EVT. Patients with Trans-Atlantic Inter-Society Consensus (TASC) A and B lesions should be treated endoluminally. EVT should be used with caution in patients with TASC C and D lesions; however, in selected patients, particularly if vein conduit is lacking and life expectancy is short, EVT is not unreasonable. For low-to-moderate risk patients with TASC C or D lesions, extensive tibial disease, and suitable vein conduit, surgical bypass remains the best limb preservation option. The primary therapeutic goals are relief of rest pain, healing of ischaemic lesions, and maintenance of functional status. Haemodynamic assessment is critical following both open and EVT for CLI and aids in determining the need for further revascularization; additional interventions are required in 20-30% of CLI patients depending on the degree of ischaemia, anatomical disease extent, and mode of initial therapy. At the University of Arizona, we currently recommend that TASC A and B CLI patients undergo EVT first. TASC C and D patients should undergo bypass unless available conduit is poor, surgical risk is prohibitive, or life expectancy is limited. CLI is a serious end-of-life condition given the sobering realization that only 50-55% of CLI patients are alive with an intact limb 5 years after initial presentation.

Original languageEnglish (US)
JournalDiabetes/Metabolism Research and Reviews
Volume24
Issue numberSUPPL. 1
DOIs
StatePublished - May 2008

Fingerprint

Complementary Therapies
Ischemia
Extremities
Consensus
Hemodynamics
Medical problems
Surgery
Therapeutics
Life Expectancy
Veins
Costs
Amputation
Lower Extremity
Atherosclerosis
Maintenance
Costs and Cost Analysis
Pain

Keywords

  • Angioplasty
  • Bypass
  • Critical limb ischaemia
  • Diabetic foot
  • Ischaemia
  • Revascularization

ASJC Scopus subject areas

  • Endocrinology
  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{a46937fdd37349c9b49501bf8a9479f9,
title = "Open bypass and endoluminal therapy: Complementary techniques for revascularization in diabetic patients with critical limb ischaemia",
abstract = "The use of endovascular therapy (EVT) for lower extremity atherosclerosis is markedly increasing while open surgical bypass is in decline. The results of EVT for critical limb ischaemia (CLI) are difficult to evaluate, especially for patients with diabetes. To date, only one randomized, prospective trial has been published comparing EVT with open bypass for CLI. Although early costs and outcomes were equivalent or superior for EVT, after 2 years, surgery was associated with a significantly reduced risk of future amputation and death. Approximately, 40-50{\%} of diabetic patients with CLI can be initially treated with EVT. Patients with Trans-Atlantic Inter-Society Consensus (TASC) A and B lesions should be treated endoluminally. EVT should be used with caution in patients with TASC C and D lesions; however, in selected patients, particularly if vein conduit is lacking and life expectancy is short, EVT is not unreasonable. For low-to-moderate risk patients with TASC C or D lesions, extensive tibial disease, and suitable vein conduit, surgical bypass remains the best limb preservation option. The primary therapeutic goals are relief of rest pain, healing of ischaemic lesions, and maintenance of functional status. Haemodynamic assessment is critical following both open and EVT for CLI and aids in determining the need for further revascularization; additional interventions are required in 20-30{\%} of CLI patients depending on the degree of ischaemia, anatomical disease extent, and mode of initial therapy. At the University of Arizona, we currently recommend that TASC A and B CLI patients undergo EVT first. TASC C and D patients should undergo bypass unless available conduit is poor, surgical risk is prohibitive, or life expectancy is limited. CLI is a serious end-of-life condition given the sobering realization that only 50-55{\%} of CLI patients are alive with an intact limb 5 years after initial presentation.",
keywords = "Angioplasty, Bypass, Critical limb ischaemia, Diabetic foot, Ischaemia, Revascularization",
author = "Mills, {Joseph L}",
year = "2008",
month = "5",
doi = "10.1002/dmrr.829",
language = "English (US)",
volume = "24",
journal = "Diabetes/Metabolism Research and Reviews",
issn = "1520-7552",
publisher = "John Wiley and Sons Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Open bypass and endoluminal therapy

T2 - Complementary techniques for revascularization in diabetic patients with critical limb ischaemia

AU - Mills, Joseph L

PY - 2008/5

Y1 - 2008/5

N2 - The use of endovascular therapy (EVT) for lower extremity atherosclerosis is markedly increasing while open surgical bypass is in decline. The results of EVT for critical limb ischaemia (CLI) are difficult to evaluate, especially for patients with diabetes. To date, only one randomized, prospective trial has been published comparing EVT with open bypass for CLI. Although early costs and outcomes were equivalent or superior for EVT, after 2 years, surgery was associated with a significantly reduced risk of future amputation and death. Approximately, 40-50% of diabetic patients with CLI can be initially treated with EVT. Patients with Trans-Atlantic Inter-Society Consensus (TASC) A and B lesions should be treated endoluminally. EVT should be used with caution in patients with TASC C and D lesions; however, in selected patients, particularly if vein conduit is lacking and life expectancy is short, EVT is not unreasonable. For low-to-moderate risk patients with TASC C or D lesions, extensive tibial disease, and suitable vein conduit, surgical bypass remains the best limb preservation option. The primary therapeutic goals are relief of rest pain, healing of ischaemic lesions, and maintenance of functional status. Haemodynamic assessment is critical following both open and EVT for CLI and aids in determining the need for further revascularization; additional interventions are required in 20-30% of CLI patients depending on the degree of ischaemia, anatomical disease extent, and mode of initial therapy. At the University of Arizona, we currently recommend that TASC A and B CLI patients undergo EVT first. TASC C and D patients should undergo bypass unless available conduit is poor, surgical risk is prohibitive, or life expectancy is limited. CLI is a serious end-of-life condition given the sobering realization that only 50-55% of CLI patients are alive with an intact limb 5 years after initial presentation.

AB - The use of endovascular therapy (EVT) for lower extremity atherosclerosis is markedly increasing while open surgical bypass is in decline. The results of EVT for critical limb ischaemia (CLI) are difficult to evaluate, especially for patients with diabetes. To date, only one randomized, prospective trial has been published comparing EVT with open bypass for CLI. Although early costs and outcomes were equivalent or superior for EVT, after 2 years, surgery was associated with a significantly reduced risk of future amputation and death. Approximately, 40-50% of diabetic patients with CLI can be initially treated with EVT. Patients with Trans-Atlantic Inter-Society Consensus (TASC) A and B lesions should be treated endoluminally. EVT should be used with caution in patients with TASC C and D lesions; however, in selected patients, particularly if vein conduit is lacking and life expectancy is short, EVT is not unreasonable. For low-to-moderate risk patients with TASC C or D lesions, extensive tibial disease, and suitable vein conduit, surgical bypass remains the best limb preservation option. The primary therapeutic goals are relief of rest pain, healing of ischaemic lesions, and maintenance of functional status. Haemodynamic assessment is critical following both open and EVT for CLI and aids in determining the need for further revascularization; additional interventions are required in 20-30% of CLI patients depending on the degree of ischaemia, anatomical disease extent, and mode of initial therapy. At the University of Arizona, we currently recommend that TASC A and B CLI patients undergo EVT first. TASC C and D patients should undergo bypass unless available conduit is poor, surgical risk is prohibitive, or life expectancy is limited. CLI is a serious end-of-life condition given the sobering realization that only 50-55% of CLI patients are alive with an intact limb 5 years after initial presentation.

KW - Angioplasty

KW - Bypass

KW - Critical limb ischaemia

KW - Diabetic foot

KW - Ischaemia

KW - Revascularization

UR - http://www.scopus.com/inward/record.url?scp=44949260197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44949260197&partnerID=8YFLogxK

U2 - 10.1002/dmrr.829

DO - 10.1002/dmrr.829

M3 - Article

C2 - 18384110

AN - SCOPUS:44949260197

VL - 24

JO - Diabetes/Metabolism Research and Reviews

JF - Diabetes/Metabolism Research and Reviews

SN - 1520-7552

IS - SUPPL. 1

ER -